Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brechignac

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Blood|September 26, 2018
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myelomaAurore Perrot, Valerie Lauwers-Cances, Jill Corre, et al.
Blood|October 13, 2016
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myelomaThomas Dejoie, Jill Corre, Helene Caillon, et al.
Blood|May 5, 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Valérie Lauwers-Cances, Margaret Macro, et al.
Blood Advances|December 24, 2019
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?Francine Garnache-Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Science (New York, N.Y.)|February 29, 2024
A far-ultraviolet-driven photoevaporation flow observed in a protoplanetary diskOlivier Berné, Emilie Habart, Els Peeters, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Blood|September 26, 2018
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myelomaAurore Perrot, Valerie Lauwers-Cances, Jill Corre, et al.
Blood|October 13, 2016
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myelomaThomas Dejoie, Jill Corre, Helene Caillon, et al.
Blood|May 5, 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Valérie Lauwers-Cances, Margaret Macro, et al.
Blood Advances|December 24, 2019
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?Francine Garnache-Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Science (New York, N.Y.)|February 29, 2024
A far-ultraviolet-driven photoevaporation flow observed in a protoplanetary diskOlivier Berné, Emilie Habart, Els Peeters, et al.
Pageof 6